A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
← catalyst calendarNCT07041099 · readout in 574 d
Sponsored by Cullinan Therapeutics Inc. (industry) · CGEM — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
36estimated
Sites
14
Countries
France, Germany, Italy +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-01 | actual | When the study began enrolling |
| Primary completion | 2028-03-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sjögren
- Sjogren Disease
- Sjogren's Syndrome
Intervention
- Drug: CLN-978
Primary outcome
what the primary-completion date above is the date OFSafety and Tolerability
measured 48 weeks
Permalink · CGEM's whole pipeline · Catalyst calendar · Every registered study · What changed